Exclusive Summary

• Pioneering Status: Positioned as one of the world's first TB mRNA vaccines to complete preclinical research and enter exploratory clinical trials (IIT), aiming for First-in-class status.
• Proprietary Platform: Developed on a fully independent mRNA platform with AI-assisted design and proprietary delivery systems, bypassing major IP barriers for global licensing.
• Addressing Global Unmet Needs: Targets Tuberculosis, a top global infectious killer where the century-old BCG vaccine lacks efficacy in adults; mRNA offers a promising solution for superior cellular immunity.

Asset Materials

Contact Us for Full Materials